Expression of Mutated Epidermal Growth Factor Receptor by Non-Small Cell Lung Carcinomas

摘要: The development of novel immunotherapy strategies for non-small cell lung cancer (NSCLC) will be facilitated by the identification tumor-specific targets. Although epidermal growth factor receptor (EGFR) is overexpressed in many cases NSCLC, its wide distribution normal tissue may limit suitability as an immunotherapeutic target. However, mutations within EGFR that are unique to malignancies provide specific targets intervention. For example, one mutant form, type III deletion EGFR, has been identified glioblastomas contains a peptide sequence extracellular domain which detectable anti-peptide antisera. In this study, prevalence mutation NSCLC was determined. Thirty-two frozen sections primary were examined immunocytochemistry determine presence native and mutated EGFR. Native 12 32 diffuse cellular five (16%) specimens (2 13 squamous, 2 mixed, 0 10 adenocarcinoma, 1 7 undifferentiated). This not detected breast, lung, skin, ovary, colon, kidney, endometrium, placenta. mutant, expressed some molecularly defined, antigen cancer.